Murray Stahl’s Beam Therapeutics BEAM Stock Holding History

Murray Stahl’s Portfolio BEAM Stock Details BEAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$288K	Sell	8,388 -403	-5%	-$12.2K	﹤0.01%	264
2026 Q1	$209K	Sell	8,791 -403	-4%	-$11.2K	﹤0.01%	297
2025 Q4	$255K	Sell	9,194 -403	-4%	-$10.3K	﹤0.01%	270
2025 Q3	$233K	Buy	+9,597	New	+$191K	﹤0.01%	287
2025 Q1	–	Sell	-9,597	Closed	-$238K	–	351
2024 Q4	$238K	Buy	9,597 +403	+4%	+$10.3K	﹤0.01%	293
2024 Q3	$225K	Sell	9,194 -403	-4%	-$10.4K	﹤0.01%	300
2024 Q2	$225K	Hold	9,597	–	–	﹤0.01%	277
2024 Q1	$317K	Hold	9,597	–	–	0.01%	249
2023 Q4	$261K	Sell	9,597 -403	-4%	-$10K	0.01%	263
2023 Q3	$241K	Hold	10,000	–	–	﹤0.01%	265
2023 Q2	$319K	Hold	10,000	–	–	0.01%	258
2023 Q1	$306K	Buy	+10,000	New	+$395K	0.01%	256

Other funds holding BEAM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Murray Stahl's BEAM Position: Q2 2026 in Review

Murray Stahl reduced its Beam Therapeutics (BEAM) stake by 4.6% in Q2 2026, selling an estimated $12.2K and leaving 8,388 shares worth $288K. The position accounts for ﹤0.01% of the portfolio, ranked #264.

Murray Stahl first reported a position in BEAM in Q1 2023 and has held it in 12 quarters since. The position peaked at $319K in Q2 2023. 275 funds tracked by Wall St. Rank hold BEAM as of Q2 2026.

Murray Stahl held 8,388 shares of Beam Therapeutics worth $288K as of Q2 2026.
Murray Stahl sold 403 Beam Therapeutics shares in Q2 2026, an estimated $12.2K.
Beam Therapeutics made up ﹤0.01% of Murray Stahl's portfolio in Q2 2026, its #264 holding.
Murray Stahl first reported a position in Beam Therapeutics in Q1 2023 and has held it in 12 quarters since.
Murray Stahl's Beam Therapeutics position peaked at $319K in Q2 2023.
275 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2026.

Based on Horizon Kinetics Asset Management's 13F filing for Q2 2026, filed 11 Aug 2026.